Silicon Valley Medical Technologies ( SIVMED ) was founded as a research and development house. In the beginning. SIVMED performed its ain basic research. obtained patents on promising engineerings. and so either sold or licensed the engineerings to other houses which marketed the merchandises. The house has since so grown and is now contracted to execute research and proving for larger familial technology houses. biotechnology houses. the US authorities. and is now widely recognized as the leader in an emerging growing industry. SIVMED’s laminitiss were comparatively affluent persons when they started company. and they committed a great trade of their ain financess to the venture. Their personal financess. nevertheless. were shortly exhausted by the extreme and rapid growing of the company. This caused them to hold to raise capital from outside resources. The borrowed to a great extent for a few old ages until all financess were used. They so turned their sights to publishing both preferable and common equity.
SIVMED is organized into 2 divisions: the Clinical Research Division and the Genetic Engineering Division. The two divisions are both located in the same edifices. but the equipment they use and their forces are rather different. In recent old ages. competition in this market has become stiffer and other big biotechnology houses have begun to acknowledge the chances in SIVMED’s research lines. This increased competition has forced the board of managers at SIVMED to upgrade their resources and use state-of-the-art techniques in its managerial procedures every bit good as in its technological procedures. The fiscal frailty president has developed an estimation for the houses cost of capital to utilize in capital budgeting determinations. He has requested that this cost of capital estimation and analysis be completed for the following board of managers run intoing.
Section 1 of this study discusses and analyzes the houses cost of capital. It begins with a treatment of the leaden mean cost of capital ( WACC ) and the cost constituents that make it up. The cost constituents are the costs of debt. preferable stock. and common stock. Using the cost equations shown in Appendix B on page 7. the cost of debt is calculated to be 6. 6 % . the cost of preferable stock is 10. 58 % . and the mean cost of common stock is 15. 0 % . Section 1 so continues with a treatment and computation of cost of new common stock. The cost of new common stock is calculated at 16. 58 % . Finally. the subdivision ends with a treatment on the book-value and market-value weight constituents of the WACC.
Section II of this study discusses the houses fringy cost of capital ( MCC ) . This treatment is accompanied by a MCC Schedule in Appendix D on page 9. which shows what SIVMED’s cost of capital would be for different degrees of new funding.
Section 1: Weighted Average Cost of CapitalWeighted Average Cost of Capital ( WACC ) is a computation of a firm’s cost of capital. A houses WACC is the overall needed return on the house as a whole and is frequently used by direction to find the feasibleness of growing or enlargement chances. For this ground. new. or fringy. costs are used in its computation. WACC is calculated by multiplying the cost of each capital constituent by its relative weight and so summing so together. The capital constituents included in this computation are a houses after-tax costs of debt. preferable stock. and common stock.
DebtThe first constituent of a houses WACC is its cost of debt. This is the effectual rate that a company pays on its current debt. Because involvement disbursals on debt are deductible. the after-tax cost is used in its computation. Cost of debt is calculated by multiplying the before-tax rate by one subtraction the fringy revenue enhancement rate. As given in the Silicon Valley instance assignment press release. SIVMED’s long-run debt consists of 9. 5 % voucher. biannual payment bonds with 15 old ages to adulthood. The bonds last traded at a monetary value of $ 891. 00 per $ 1. 000 par value bond. Given this information. SIVMED’s cost of debt is calculated at 6. 6 % .
It is frequently questionable as to whether floatation costs are included in the computation of a houses cost of debt. Flotation costs are the costs associated with the issue of new securities. These costs should be included in this computation. For debt. nevertheless. this value is normally ignored because it is really little and does non hold a important affect on the result of the computation. Besides. when sing whether to utilize the nominal cost of debt or the effectual yearly rate. the cost of debt requires the usage of the nominal cost to guarantee its consistence with other fiscal computations.
SIVMED usually issues 30-year long-run bonds. Because of this. the estimation of its cost of debt based on 15-year bonds is non really accurate. For the 15-year cost to better stand for the 30-year cost. an extra cost. or premium. could be added to the bonds purchase monetary value.
Presently. SIVMED’s outstanding bonds are non callable. intending that they can non be redeemed by the issuer prior to its adulthood. The houses cost of debt could be affected if these bonds were callable. If the bonds were callable they would hold to cipher both its cost to name and its cost to adulthood. The cost of debt would so be the lower of these two values.
Preferred StockThe 2nd constituent of a houses WACC is its cost of preferable stock. The cost of preferable stock is defined as the declared dividend rate of the single preferable stock issue. It calculated by spliting the one-year preferable stock dividends by the net monetary value of the preferable stock. SIVMED’s preferable stock pays a dividend of $ 2. 50 per one-fourth. has a par value of $ 100. 00. is non-callable and ageless. and is traded in the nonprescription ( OTC ) market at a current monetary value of $ 104. 00 per portion. Using this information. SIVMED’s cost of preferable stock is calculated at 9. 8 % .
Although the houses before-tax output to investors is lower than the output on its debt. SIVMED’s preferable stock is more hazardous to investors than its debt. This is due chiefly to the fact that most of the preferable stock is owned by corporations and a important part of their preferable stock dividend is exempt.
If SIVMED were to ordain a compulsory salvation proviso stipulating that the house must deliver the issue in 5 old ages at the monetary value of $ 110. 00 per portion. its cost of preferable stock would increase from 9. 8 % to 11. 0 % .
Common StockThe 3rd constituent of a houses WACC is its cost of common stock. or cost of maintained net incomes. This is the cost of internally generated financess or the dividends given up by the common shareholders. The ground that there is a cost associated with maintained net incomes is because of the chance for an investor to turn a net income from reinvesting any dividends paid to them alternatively of merely retaining it.
1. The Capital Asset Pricing Model ( CAPM ) attack calculates the cost of common stock as the riskless rate plus a hazard premium that is multiplied by the stock beta coefficient. Given that SIVMED’s current output on long-run T-bonds is 8. 0 % . its market hazard premium is estimated at 6. 0 % points over Treasury bonds. and the stocks beta coefficient is 1. 2. their cost of common stock is calculated by the CAPM attack to be 15. 2 % .
It is considered that the T-bond rate is a better estimation of the riskless rate than the T-bill rate. The lone scenario that makes the T-bill rate favorable over that of a T-bond would be if this were a absolutely riskless market. Unfortunately. the world is that there is no such thing as a absolutely riskless environment. doing the T-bond rate more favourable.
Within the computation of the cost of common stock is the stocks beta coefficient. There are three different betas that might be used ; historical betas. adjusted historical betas. or cardinal betas.
•Historical betas are estimated by a arrested development of historical returns on an investing against the historical returns on a market.
•Adjusted betas are estimated by taking a natural beta times 0. 67 and adding it to 1. 00 times 0. 33.
•Fundamental betas are estimated in respects to the basicss of the peculiar concern with which a house is involved.
There are different methods to which SIVMED could cipher its market hazard premium for usage in a CAPM cost of common stock computation. One method could be to obtain it from some other organisation. Another method could be to cipher it within the house by roll uping historical informations on the riskless rate and return on market.
2. The Discounted Cash Flow ( DCF ) method is another manner of ciphering the cost of common stock. Using this method. all future hard currency flows are estimated and discounted to give them a present value. SIVMED’s estimated cost of common stock. utilizing the DCF method. is calculated at 14. 8 % .
SIVMED has. for the past twosome of old ages. had a 14. 0 % mean return on equity ( ROE ) and has paid out about 25. 0 % of it net income as dividends. Using this information. the houses expected future growing rate is estimated to be 10. 5 % . Inserting this value into the equation for DCF will. yet once more. find an estimated cost of common stock for SIVMED. This cost is estimated at 15. 32 % .
3. SIVMED’s cost of common stock and besides be estimated by yet another method. the Bond-Yield-plus-Risk-Premium method. This method is used where dependable inputs for neither the CAPM nor the DCF attacks are available. It is calculated by adding a houses bond output and its corresponding hazard premium. Using this attack and an estimated bond hazard premium of 5. 0 % . SIVMED’s cost of common stock is estimated at 15. 0 % .
Using equal weights to each of the three estimations calculated above and taking their norm. the concluding estimation for SIVMED’s cost of common stock is 15. 0 % .
Cost of New Common StockThe cost of new common stock is another method of ciphering a houses cost of common stock. It is similar to the DCF method except that it accounts for floatation costs. Flotation costs are the per centum cost of publishing new common stock. Give a floatation cost of 30. 0 % . SIVMED’s cost of new common stock is estimated at 16. 85 % .
Component Weights of WACCThere are two types of weights that can be applied to the constituents used to cipher the WACC. These two types are Book-Value weights and Market-Value weights.
1. Book-value weights of the WACC constituents can be determined by merely mentioning to the houses balance sheet for the entire sum of long-run debt. preferable stock. and common stock. The weights are so calculated by finding the proportion that each beginning of capital is of the entire capital. SIVMED’s book-value weights are calculated to be 39. 31 % for long-run debt. 9. 63 % for preferable stock. and 51. 06 % for common stock.
2. Market-value weights are different than book-value weights in that. while book-value weights are calculated from historical book values. market-value weights are determined from the uninterrupted recalculation of the values of each type of capital. This makes market-value weights more appropriate values to utilize when ciphering a houses WACC. The market-value weight for SIVMED’s long-run debt is calculated at 11. 66 % . 3. 34 % for preferable stock. and 85. 0 % for common stock.
Section 2: Fringy Cost of CapitalA houses Marginal Cost of Capital ( MCC ) is their cost of obtaining an extra dollar of new capital. It can besides be thought of as the leaden mean cost of the last dollar of new capital raised. The MCC agenda is a graph the relates the houses weighted norm of each dollar of capital to the entire sum of new capital raised. It reflects altering costs. depending on the sum of capital raised.
Using the information provided in the tabular array in Appendix D on page 9. it has been determined that. for new financing up to $ 3 million. SIVMED’S WACC can increase to 12. 08 % before it is forced to sell new common stock. For new funding of more than $ 3 million. their WACC can increase to 13. 16 % . These costs of capital should non be used by both divisions at SIVMED. The two divisions have different hazards associated with them doing this an inappropriate value for both.
SIVMED’s MCC agenda would non stay changeless beyond the maintained net incomes interruption point. no affair how much capital is raised. This is because of the simple fact that the cost of capital additions as the house raises more and more capital. Another factor that may impact the MCC agenda is depreciation. It plays an of import function because. if ignored. it could minimize the houses net hard currency flows.
Brigham. Eugene F. . and Joel F. Houston. Fundamentalss of Financial Management. . “Chapter 8 spreadsheet module” .
Brigham. Eugene F. . and Joel F. Houston. Fundamentalss of Financial Management. . “Chapter 9 spreadsheet module” .
Brigham. Eugene F. . and Joel F. Houston. Fundamentalss of Financial Management. . “Chapter 10 spreadsheet module” .
Brigham. Eugene F. . and Joel F. Houston. Fundamentalss of Financial Management. Thomson: South-Western Publishers. Eleventh Ed. 2007.